Drug Combination Improves Outcome For Advanced Non-Small Cell Lung Cancer

A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC). Results from the Phase III “ATLAS” trial were presented today by Dr. Vincent Miller of Memorial Sloan-Kettering Cancer Center (MSKCC) at the American Society of Clinical Oncology Annual Meeting.

More: continued here

Filed under: Clinical Trials on June 1st, 2009